Serum phospho-tau217, a biomarker of tau protein that can be detected in the blood, is increased in preclinical Alzheimer’s disease and may have clinical utility for the early detection of brain pathology.
Most healthcare providers know that compassionate care and honest conversations with patients can lead to trusting relationships and better outcomes. Those relationships are even more important as a patient edges toward the end of life, or received a diagnosis of chronic or terminal illness. This is where palliative care comes in.
A population-based cohort study showed that exposure to antibiotics during the first two years of life is associated with increased rates of subsequently developing asthma, allergic rhinitis, atopic dermatitis, attention deficit hyperactivity disorder, celiac disease, and obesity.
Designated groups first, but approval is for all 16 years of age and older
December 11, 2020
The Food and Drug Administration’s vaccine advisory committee has approved the use of the COVID-19 vaccine developed by Pfizer Inc. (NYC) and BioNTech (Mainz, DEU) in the United States for those ages 16 years and older. The first doses will go to healthcare workers and long-term care residents.
Standard would protect healthcare workers from infectious disease
November 24, 2020
In acknowledged underestimates, the Centers for Disease Control and Prevention reports tens of thousands of healthcare workers have acquired COVID-19 and hundreds have died. With CDC guidelines nonregulatory, politicized, and too often ignored during the pandemic, the question arises: Could an enforceable infectious disease standard by the Occupational Safety and Health Administration have saved lives during the pandemic?
Healthcare workers may be vigilant with personal protective equipment around COVID-19 patients, but inadvertently expose themselves to colleagues when they take breaks, socialize, and eat. Part of the problem is healthcare workers are experiencing PPE fatigue and may be tempted to removed gear for brief respites when possible.
In a randomized, double-blind, placebo-controlled trial of Fortasyn Connect (Souvenaid), a nutraceutical drink, patients with prodromal Alzheimer’s disease demonstrated, over a 36-month period, a slower decline in cognitive functions compared to the control group.
This postmortem study of multiple sclerosis (MS) patients evaluated the presence and pathological significance of extracranial systemic and cerebral small vessel disease in patients with MS compared to healthy controls. MS patients had less systemic vascular disease and more small vessel disease in the brain compared to controls.